Compound tracker
CYB003 / deuterated psilocin analog.
A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
1 trial rows 0 update rows Latest checked: May 15, 2026 All trials Claim boundary
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Related update rows are shown only when they include visible Last checked text and an explicit Claim boundary.
Backlinks
This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.
Trial rows
NCT06793397 Phase 3 Recruiting updated May 15, 2026
- Condition
- Major Depressive Disorder
- Sponsor / institution
- Cybin IRL Limited; Worldwide Clinical Trials
- Start date
- Dec 10, 2025
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; CYB003 remains investigational; recruiting/Phase 3 status does not establish efficacy, safety, approval, label, reimbursement, or access. Registry: Phase 3 EMBRACE multicenter randomized quadruple-masked trial, estimated n=330, CYB003 8mg or 16mg in two dosing sessions about three weeks apart vs placebo, adjunctive to antidepressants with psychological support; primary outcome MADRS through Day 84/End of Trial; estimated completion 2027-05-08.
Related updates
No source-update rows are currently linked to this compound.
Conditions touched
Major Depressive Disorder